Williams & Novak’s Trinity Biotech TRIB Stock Holding History

Williams & Novak’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-4,685	Closed	-$54.6K	–	162
2026 Q2	$54.6K	Buy	4,685 +1,097	+31%	+$20.3K	0.04%	136
2026 Q1	$64.4K	Buy	3,588 +478	+15%	+$10.6K	0.05%	124
2025 Q4	$73.8K	Buy	3,110 +2,710	+678%	+$79.9K	0.06%	127
2025 Q3	$12.5K	Sell	400 -333	-45%	-$10.5K	0.01%	139
2025 Q2	$14.3K	Buy	733 +126	+21%	+$2.53K	0.01%	133
2025 Q1	$10.4K	Buy	+607	New	+$14.4K	0.01%	126
2024 Q1	–	Sell	-67	Closed	-$4.29K	–	89
2023 Q4	$4.29K	Buy	+67	New	+$4.8K	﹤0.01%	91

Other funds holding TRIB

Hunter Associates Investment Management Pittsburgh, Pennsylvania $860M AUM 22.54% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Williams & Novak's TRIB Position: Q3 2026 in Review

Williams & Novak sold out of Trinity Biotech (TRIB) in Q3 2026, closing a stake of 4,685 shares — an estimated $54.6K sold.

Williams & Novak first reported a position in TRIB in Q4 2023 and held it in 7 quarters. The position peaked at $73.8K in Q4 2025. 2 funds tracked by Wall St. Rank hold TRIB as of Q3 2026.

Williams & Novak reported no remaining Trinity Biotech position as of Q3 2026 after selling out during the quarter.
Williams & Novak sold 4,685 Trinity Biotech shares in Q3 2026, an estimated $54.6K.
Williams & Novak first reported a position in Trinity Biotech in Q4 2023 and held it in 7 quarters.
Williams & Novak's Trinity Biotech position peaked at $73.8K in Q4 2025.
2 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2026.

Based on Williams & Novak's 13F filing for Q3 2026, filed 9 Oct 2026.